Setareh Shamsili

1.6k total citations
14 papers, 1.1k citations indexed

About

Setareh Shamsili is a scholar working on Molecular Biology, Oncology and Neurology. According to data from OpenAlex, Setareh Shamsili has authored 14 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Neurology. Recurrent topics in Setareh Shamsili's work include Autoimmune Neurological Disorders and Treatments (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Setareh Shamsili is often cited by papers focused on Autoimmune Neurological Disorders and Treatments (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Setareh Shamsili collaborates with scholars based in Netherlands, United States and Spain. Setareh Shamsili's co-authors include Peter Sillevis Smitt, Herbert Hooijkaas, Martin J. van den Bent, B. de Leeuw, Charles J. Vecht, Bronno van der Holt, Raquel Sánchez‐Valle, Josep Dalmau, Jérôme Honnorat and Francesc Graus and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Brain.

In The Last Decade

Setareh Shamsili

12 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Setareh Shamsili Netherlands	9	668	364	258	215	116	14	1.1k
Ruth Ho United States	9	466 0.7×	619 1.7×	126 0.5×	169 0.8×	65 0.6×	10	879
Helen Travers United Kingdom	11	254 0.4×	448 1.2×	333 1.3×	104 0.5×	75 0.6×	16	905
Tobias Sperka Germany	13	212 0.3×	548 1.5×	63 0.2×	216 1.0×	57 0.5×	14	1.0k
Nicholas T. Potter United States	15	228 0.3×	685 1.9×	494 1.9×	258 1.2×	111 1.0×	37	1.2k
Toshiki Yamasaki Japan	16	338 0.5×	214 0.6×	97 0.4×	151 0.7×	32 0.3×	62	967
Walter J. Jessen United States	16	420 0.6×	471 1.3×	46 0.2×	100 0.5×	66 0.6×	20	951
Mohini Lutchman United States	14	257 0.4×	325 0.9×	77 0.3×	56 0.3×	35 0.3×	22	733
Hayley Spearman United Kingdom	13	202 0.3×	376 1.0×	60 0.2×	95 0.4×	145 1.3×	17	726
Abhik Ray Chaudhury United States	17	144 0.2×	419 1.2×	55 0.2×	401 1.9×	93 0.8×	26	1.0k
Takafumi Jigami Japan	10	135 0.2×	630 1.7×	103 0.4×	152 0.7×	45 0.4×	10	863

Countries citing papers authored by Setareh Shamsili

Since Specialization

Citations

This map shows the geographic impact of Setareh Shamsili's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Setareh Shamsili with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Setareh Shamsili more than expected).

Fields of papers citing papers by Setareh Shamsili

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Setareh Shamsili. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Setareh Shamsili. The network helps show where Setareh Shamsili may publish in the future.

Co-authorship network of co-authors of Setareh Shamsili

This figure shows the co-authorship network connecting the top 25 collaborators of Setareh Shamsili. A scholar is included among the top collaborators of Setareh Shamsili based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Setareh Shamsili. Setareh Shamsili is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Solomon, Scott R., Pau Montesinos, Aziz Nazha, et al.. (2021). Updated results from DIAMOND-01 (CLI24-001) trial: A phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia.. Journal of Clinical Oncology. 39(15_suppl). 7023–7023. 3 indexed citations

Göller, Kristina, Jan Maciej Zaucha, Ewa Zarzycka, et al.. (2021). RVU120 (SEL120) CDK8/19 Inhibitor - a Drug Candidate for the Treatment of MDS Can Induce Erythroid Differentiation. Blood. 138(Supplement 1). 1518–1518.

Abboud, Camille N., Gautam Borthakur, Scott R. Solomon, et al.. (2021). CLI120-001 Phase Ib Study of RVU120(SEL120) in Patients with AML and High Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation. Blood. 138(Supplement 1). 3418–3418.

Calvo, Emiliano, María Alsina, Jan H.M. Schellens, et al.. (2016). Abstract CT050: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors. Cancer Research. 76(14_Supplement). CT050–CT050. 12 indexed citations

Loo, Pieter Fokko van, et al.. (2015). Preclinical Evaluation of MCLA117, a CLEC12AxCD3 Bispecific Antibody Efficiently Targeting a Novel Leukemic Stem Cell Associated Antigen in AML. Blood. 126(23). 325–325. 28 indexed citations

Geuijen, Cecile, Therèse Visser, Willem Bartelink, et al.. (2014). Preclinical activity of MCLA-128, an ADCC enhanced bispecific IgG1 antibody targeting the HER2:HER3 heterodimer.. Journal of Clinical Oncology. 32(15_suppl). 560–560. 12 indexed citations

Cheson, Bruce D., Nancy L. Bartlett, Julie M. Vose, et al.. (2011). A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B‐cell lymphoma. Cancer. 118(12). 3128–3134. 96 indexed citations

Shamsili, Setareh, B. de Leeuw, Esther Hulsenboom, Dick Jaarsma, & Peter Sillevis Smitt. (2009). A new paraneoplastic encephalomyelitis autoantibody reactive with the axon initial segment. Neuroscience Letters. 467(2). 169–172. 8 indexed citations

Giaccone, Giuseppe, Petr Zatloukal, Jaromı́r Roubec, et al.. (2009). Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(27). 4481–4486. 210 indexed citations

10.

Cheson, Bruce D., J. M. Vose, Nancy L. Bartlett, et al.. (2009). Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL). Journal of Clinical Oncology. 27(15_suppl). 8502–8502. 12 indexed citations

11.

Giaccone, Giuseppe, Petr Zatloukal, Jaromı́r Roubec, et al.. (2007). A phase II, monotherapy study of YM155, a novel survivin suppressant, in previously treated advanced stage non-small cell lung cancer (NSCLC). Molecular Cancer Therapeutics. 6. 2 indexed citations

12.

Shamsili, Setareh, Jan W. Gratama, Herbert Hooijkaas, et al.. (2006). An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. Journal of Neurology. 253(1). 16–20. 128 indexed citations

13.

Shamsili, Setareh, B. de Leeuw, Martin J. van den Bent, et al.. (2003). Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 126(6). 1409–1418. 359 indexed citations

14.

Shamsili, Setareh, Raquel Sánchez‐Valle, Albert Saiz, et al.. (2003). Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin’s disease. Neurology. 60(2). 230–234. 209 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact